269 related articles for article (PubMed ID: 26401762)
21. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
22. Photobiomodulation in experimental models of Alzheimer's disease: state-of-the-art and translational perspectives.
Huang Z; Hamblin MR; Zhang Q
Alzheimers Res Ther; 2024 May; 16(1):114. PubMed ID: 38773642
[TBL] [Abstract][Full Text] [Related]
23. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
Knopman DS; Haeberlein SB; Carrillo MC; Hendrix JA; Kerchner G; Margolin R; Maruff P; Miller DS; Tong G; Tome MB; Murray ME; Nelson PT; Sano M; Mattsson N; Sultzer DL; Montine TJ; Jack CR; Kolb H; Petersen RC; Vemuri P; Canniere MZ; Schneider JA; Resnick SM; Romano G; van Harten AC; Wolk DA; Bain LJ; Siemers E
Alzheimers Dement; 2018 Apr; 14(4):563-575. PubMed ID: 29653607
[TBL] [Abstract][Full Text] [Related]
24. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project.
Ritchie K; Ropacki M; Albala B; Harrison J; Kaye J; Kramer J; Randolph C; Ritchie CW
Alzheimers Dement; 2017 Feb; 13(2):186-195. PubMed ID: 27702619
[TBL] [Abstract][Full Text] [Related]
25. Past to Future: What Animal Models Have Taught Us About Alzheimer's Disease.
Martini AC; Forner S; Trujillo-Estrada L; Baglietto-Vargas D; LaFerla FM
J Alzheimers Dis; 2018; 64(s1):S365-S378. PubMed ID: 29504540
[TBL] [Abstract][Full Text] [Related]
26. Developing Trojan horses to induce, diagnose and suppress Alzheimer's pathology.
Aziz AA; Amtul Z
Pharmacol Res; 2019 Nov; 149():104471. PubMed ID: 31590012
[TBL] [Abstract][Full Text] [Related]
27. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?
Mullane K; Williams M
Biochem Pharmacol; 2020 Jul; 177():113945. PubMed ID: 32247851
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's disease: many failed trials, so where do we go from here?
Reiss AB; Glass AD; Wisniewski T; Wolozin B; Gomolin IH; Pinkhasov A; De Leon J; Stecker MM
J Investig Med; 2020 Aug; 68(6):1135-1140. PubMed ID: 32699179
[TBL] [Abstract][Full Text] [Related]
29. Mapping the road forward in Alzheimer's disease.
Holtzman DM; Goate A; Kelly J; Sperling R
Sci Transl Med; 2011 Dec; 3(114):114ps48. PubMed ID: 22190237
[TBL] [Abstract][Full Text] [Related]
30. Research design issues: antialuminum drug studies in Alzheimer's disease.
Shore D; Wyatt RJ
Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
[TBL] [Abstract][Full Text] [Related]
31. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
Ritchie CW; Russ TC; Banerjee S; Barber B; Boaden A; Fox NC; Holmes C; Isaacs JD; Leroi I; Lovestone S; Norton M; O'Brien J; Pearson J; Perry R; Pickett J; Waldman AD; Wong WL; Rossor MN; Burns A
Alzheimers Res Ther; 2017 Oct; 9(1):85. PubMed ID: 29070066
[TBL] [Abstract][Full Text] [Related]
32. Meeting report of the fifth annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research.
Sasner M; Onos KD; Territo PR; Sukoff Rizzo SJ
Alzheimers Dement; 2024 Feb; ():. PubMed ID: 38400713
[TBL] [Abstract][Full Text] [Related]
33. Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups.
Perneczky R; Kempermann G; Korczyn AD; Matthews FE; Ikram MA; Scarmeas N; Chetelat G; Stern Y; Ewers M
BMC Med; 2019 Feb; 17(1):47. PubMed ID: 30808345
[TBL] [Abstract][Full Text] [Related]
34. Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia.
Shepherd A; Tyebji S; Hannan AJ; Burrows EL
J Mol Neurosci; 2016 Nov; 60(3):371-382. PubMed ID: 27637601
[TBL] [Abstract][Full Text] [Related]
35. Illustrating idiographic methods for translation research: moderation effects, natural clinical experiments, and complex treatment-by-subgroup interactions.
Ridenour TA; Wittenborn AK; Raiff BR; Benedict N; Kane-Gill S
Transl Behav Med; 2016 Mar; 6(1):125-34. PubMed ID: 27012260
[TBL] [Abstract][Full Text] [Related]
36. Disease-modifying therapies in Alzheimer's disease.
Salloway S; Mintzer J; Weiner MF; Cummings JL
Alzheimers Dement; 2008 Mar; 4(2):65-79. PubMed ID: 18631951
[TBL] [Abstract][Full Text] [Related]
37. Nanotechnology Therapy for Alzheimer's Disease Memory Impairment Attenuation.
Ribarič S
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499311
[TBL] [Abstract][Full Text] [Related]
38. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
[TBL] [Abstract][Full Text] [Related]
39. Down syndrome and Alzheimer's disease: Common pathways, common goals.
Hartley D; Blumenthal T; Carrillo M; DiPaolo G; Esralew L; Gardiner K; Granholm AC; Iqbal K; Krams M; Lemere C; Lott I; Mobley W; Ness S; Nixon R; Potter H; Reeves R; Sabbagh M; Silverman W; Tycko B; Whitten M; Wisniewski T
Alzheimers Dement; 2015 Jun; 11(6):700-9. PubMed ID: 25510383
[TBL] [Abstract][Full Text] [Related]
40. Current understanding of Alzheimer's disease diagnosis and treatment.
Weller J; Budson A
F1000Res; 2018; 7():. PubMed ID: 30135715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
